StockpollyBeta
Get App
Popularity #3,603
KZIA · NASDAQ · Biotechnology

Kazia Therapeutics (ADR) (KZIA)

Develops paxalisib and licensed oncology programs for treatment-resistant cancers.

$10.12
vs last close−0.80 (−7.37%)

  1. Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

    PRNewsWire

  2. Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

    PRNewsWireClinical

  3. Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

    Seeking AlphaEarnings

  4. Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

    PRNewsWireClinical

  5. Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

    PRNewsWireFinancing

  6. Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

    PRNewsWireFinancing

  7. Kazia Therapeutics Limited Announces Proposed Public Offering

    PRNewsWireFinancing

  8. Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

    PRNewsWireClinical

  9. Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

    GlobeNewsWire

  10. Kazia Therapeutics Appoints James Levine as Chief Financial Officer

    PRNewsWire

  11. Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

    PRNewsWire

  12. Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

    PRNewsWire

  13. Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

    PRNewsWire

  14. Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

    PRNewsWire

  15. Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

    PRNewsWire

  16. Short Interest in Novogen Limited (NASDAQ:KZIA) Decreases By 35.4%

    Defense World

  17. Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis

    Defense World

  18. Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

    PRNewsWire

  19. What's Going On With Cancer Firm Kazia Therapeutics

    Benzinga

  20. Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

    PRNewsWire

  21. Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

    PRNewsWire

  22. Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

    PRNewsWire

  23. Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

    PRNewsWire

  24. Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

    PRNewsWire